{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-028283","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-06-11T20:15:23+00:00","discovered_at":"2026-06-11T20:16:02.345280+00:00","generated_at":"2026-06-11T20:27:43.279676+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AIM ImmunoTech prices $2.65 million registered direct offering and private placement","bullets":["Company issued 2,554,119 registered shares and 771,503 unregistered shares at $0.5189 per share for gross proceeds of ~$2.65M.","Also issued pre-funded warrants for 1,782,616 shares at $0.001 exercise price and Class J warrants for 10,216,476 shares at $0.5189.","Offering includes placement agent warrants for 306,494 shares at $0.6486 per share; Ladenburg Thalmann acted as placement agent.","Net proceeds will fund clinical trial activities, manufacture of clinical drug supply, and working capital.","Closing expected on or about June 10, 2026, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-028283","json":"https://secwatch.observer/filing/0001493152-26-028283.json","markdown":"https://secwatch.observer/filing/0001493152-26-028283.md","text":"https://secwatch.observer/filing/0001493152-26-028283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:27:43.279676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49a4b573995e6ebecc36ac1c26ef1383bf972bdb","claim":"AIM ImmunoTech Inc. issued up to 1,782,616 shares of Common Stock of warrant to institutional investors.","evidence_excerpt":"pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,782,616 shares of Common Stock (the “Pre-Funded Warrant Shares”) at an exercise price of $0.001","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"up to 1,782,616 shares of Common Stock"},{"label":"Purchaser","value":"institutional investors"}],"fact_type":"equity_issuance"},{"claim_id":"8c0ed256f632a6a17189e3ea17bdd56f3a481540","claim":"AIM ImmunoTech Inc. issued 771,503 shares of common stock to institutional investors for $0.5189 per share.","evidence_excerpt":"the Company also agreed to issue and sell to such Investors, in a concurrent private placement, 771,503 shares of Common Stock at a per share price of $0.5189 (the “Unregistered Shares”)","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"771,503 shares"},{"label":"Purchaser","value":"institutional investors"},{"label":"Consideration","value":"$0.5189 per share"}],"fact_type":"equity_issuance"},{"claim_id":"934c977c935f31ffe8eff6ba73cc513504aa7693","claim":"AIM ImmunoTech Inc. issued 306,494 shares of Common Stock of warrant to Ladenburg Thalmann & Co. Inc..","evidence_excerpt":"The Company also agreed to issue to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase 306,494 shares of Common Stock (the “Placement Agent Warrant Shares”)","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"306,494 shares of Common Stock"},{"label":"Purchaser","value":"Ladenburg Thalmann & Co. Inc."}],"fact_type":"equity_issuance"},{"claim_id":"af2fe10fa00d8952d5a653edf7e5291d1004e2e2","claim":"AIM ImmunoTech Inc. issued up to 10,216,476 shares of Common Stock of warrant to institutional investors.","evidence_excerpt":"Class J warrants (the “Class J Warrants”) to purchase up to 10,216,476 shares of Common Stock (the “Class J Warrant Shares”), at an exercise price of $0.5189 per share","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"up to 10,216,476 shares of Common Stock"},{"label":"Purchaser","value":"institutional investors"}],"fact_type":"equity_issuance"},{"claim_id":"89e958bd110b62fa1d7b77a24637e22140a8b3a0","claim":"AIM ImmunoTech Inc. entered into Securities Purchase Agreement with institutional investors valued at Gross proceeds of approximately $1.3 million from Registered Offering, plus potential additional gro (effective 2026-06-09).","evidence_excerpt":"On June 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 2,554,119 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.5189 per share (such registered direct offering, the “Registered Offering”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"institutional investors"},{"label":"Value","value":"Gross proceeds of approximately $1.3 million from Registered Offering, plus potential additional gro"},{"label":"Effective","value":"2026-06-09"}],"fact_type":"material_agreement"},{"claim_id":"e96624825eabc0c340a6b90d5e682c152652a9ab","claim":"AIM ImmunoTech Inc. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. valued at Cash fee equal to 8.0% and management fee equal to 0.75% of aggregate gross proceeds of Offerings, p (effective 2026-06-09).","evidence_excerpt":"In connection with the Offerings, the Company also entered into a placement agency agreement, dated June 9, 2026 (the “Placement Agency Agreement”), with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”), pursuant to which the Company agreed to pay the Placement Agent a cash fee equal to 8.0%, and a management fee equal to 0.75%, of the aggregate gross proceeds of the Offerings, and reimbursed the Placement Agent for certain expenses and legal fees.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315226028283/0001493152-26-028283-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc."},{"label":"Value","value":"Cash fee equal to 8.0% and management fee equal to 0.75% of aggregate gross proceeds of Offerings, p"},{"label":"Effective","value":"2026-06-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}